MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.850
-0.230
-5.64%
After Hours: 3.900 +0.05 +1.30% 19:54 12/12 EST
OPEN
4.100
PREV CLOSE
4.080
HIGH
4.130
LOW
3.840
VOLUME
5.28M
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
0.6925
MARKET CAP
920.39M
P/E (TTM)
-7.1855
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 3d ago
Esperion Therapeutics Grants Stock Options and RSUs to New Chief Commercial Officer
Reuters · 5d ago
Weekly Report: what happened at ESPR last week (1201-1205)?
Weekly Report · 12/08 09:20
Weekly Report: what happened at ESPR last week (1124-1128)?
Weekly Report · 12/01 09:19
Esperion a new overweight at Piper Sandler on CV franchise
Seeking Alpha · 11/25 17:42
Midday Fly By: Alphabet continues ascent, fueled by AI optimism
TipRanks · 11/25 17:06
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/25 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's 
Reuters · 11/25 15:45
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.